{"schema_version":"secwatch.filing_event.v1","accession":"0001193805-24-000103","form_type":"8-K","ticker":"TCRT","cik":"0001107421","company_name":"Alaunos Therapeutics, Inc.","filed_at":"2024-01-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.379670+00:00","generated_at":"2026-06-06T15:44:38.849598+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Alaunos Therapeutics approves 1-for-15 reverse stock split effective Jan 31, 2024","bullets":["Reverse split ratio of 1-for-15 approved by Board on Jan 29, 2024; effective Jan 31 at 5:00 PM ET.","Every 15 pre-split shares combine into 1 post-split share; trading begins on split-adjusted basis Feb 1 under same symbol TCRT with new CUSIP.","Stockholders authorized split ratio range (1-for-5 to 1-for-15) at June 2023 annual meeting; Board selected 1-for-15 on Jan 12, 2024.","Equiniti Trust Company appointed as exchange agent for the reverse split."],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-24-000103","json":"https://secwatch.observer/filing/0001193805-24-000103.json","markdown":"https://secwatch.observer/filing/0001193805-24-000103.md","text":"https://secwatch.observer/filing/0001193805-24-000103.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1107421/000119380524000103/0001193805-24-000103-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1107421/000119380524000103/e619210_8k-at.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T15:44:38.849598+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}